Skip to content

Clinical study of Huangqi Guizhi Wuwu decoction in the treatment of PD peripheral neuropathy

Clinical study of Huangqi Guizhi Wuwu decoction in the treatment of PD peripheral neuropathy

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2400090455
Enrollment
Unknown
Registered
2024-09-30
Start date
2022-03-06
Completion date
Unknown
Last updated
2024-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

parkinson desease

Interventions

Treatment group:Take Huangqi Guizhi Wuwu decoction and Conventional anti-Parkinson drugs
control group:Conventional anti-Parkinson drugs

Sponsors

Guangdong Provincial People’s Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) to meet the 2015 international dyskinesia association (MDS) diagnostic criteria for Parkinson's disease and the 2016 edition of Chinese diagnostic criteria for Parkinson's disease. (2) the attending doctors of traditional Chinese medicine and above belong to those with qi deficiency and blood stagnation by "looking", "smelling", "asking" and " feel the pulse". (3) volunteer to participate in this researcher and can cooperate to complete all the examination projects.

Exclusion criteria

Exclusion criteria: (1 )receiving surgical implantation of electricity.Those who are extremely treated with deep brain stimulation; (2) those with pacemakers are not suitable for electrophysiological examination; (3) Parkinson's disease superimposed syndrome. (such as multiple system atrophy, progressive supranuclear paralysis, cortical basal ganglia degeneration, etc.) and secondary Parkinson's syndrome (such as.Ischemic cerebrovascular disease, encephalitis, poisoning, tumor, trauma, heredity, etc.); (4) schizophrenia, depression, excessive drowsiness, sleep attacks and other primary or organic mental disorders; (5) people with alcohol dependence or drug addiction; ( 6) diabetes, rheumatic immune disease, HIV infection, history of gastrointestinal surgery and severe damage of liver and kidney function.

Design outcomes

Secondary

MeasureTime frame
PD motor symptoms assessment;

Primary

MeasureTime frame
Peripheral nerve assessment;

Countries

China

Contacts

Public ContactXie Chunge

Guangdong Provincial People’s Hospital

xiaokrlian@126.com+86 137 6074 0983

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026